Evidence map›Paper›PMID 41819539›Full record

Trial reportThe European respiratory journal2026

Safety and efficacy of namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung): a randomised, double-blinded, multicentre, phase 2 study.

Bernt Van Den Blink, Surinder S Birring, Nesrin Mogulkoc, Sibel Nayci Atis, Rohit Gupta, Julien Guiot, Simon P Hart, Eva M Carmona Porquera, Hajira B Koeller, Natasha Arocho and 7 more

Abstract readRandomized Controlled TrialMulticenter StudyClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The European respiratory journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. New Therapies for Sarcoidosis: Molecular and Pathophysiological Basis.International journal of molecular sciences · 2026
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Bernt Van Den BlinkKinevant Sciences, Inc., New York, NY, USA.
Surinder S BirringCentre for Human and Applied Physiological Sciences, School of Basic and Medical Biosciences, Faculty of Life Sciences and Medicine, King's College London, London, UK.
Nesrin MogulkocDepartment of Chest Diseases, University of Ege, Izmir, Turkey.
Sibel Nayci AtisDepartment of Pulmonology, University of Mersin, Mersin, Turkey.
Rohit GuptaDepartment of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
Julien GuiotDepartment of Respiratory Medicine, CHU Liège, Liège, Belgium.
Simon P HartRespiratory Research Group, Hull York Medical School/University of Hull, Cottingham, UK.ORCID https://orcid.org/0000-0003-4606-9559
Eva M Carmona PorqueraDepartment of Pulmonary Medicine, Mayo Clinic, Rochester, MN, USA.
Hajira B KoellerKinevant Sciences, Inc., New York, NY, USA.ORCID https://orcid.org/0000-0003-3036-6313
Natasha ArochoKinevant Sciences, Inc., New York, NY, USA.
Chantal M PetitKinevant Sciences, Inc., New York, NY, USA.
Jill DenningKinevant Sciences, Inc., New York, NY, USA.
Min LinRoivant Sciences, Inc., New York, NY, USA.
Robert P BaughmanDepartment of Medicine, University of Cincinnati, Cincinnati, OH, USA.
Marlies Wijsenbeek-LourensCenter for Interstitial Lung Diseases and Sarcoidosis, Department of Respiratory Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Theodore F ReissKinevant Sciences, Inc., New York, NY, USA ted.reiss@roivant.com.
RESOLVE-Lung investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTreatment options for chronic pulmonary sarcoidosis are limited in efficacy and by tolerability concerns. Namilumab, an investigational humanised monoclonal antibody inhibiting granulocyte-macrophage colony-stimulating factor, was hypothesised to downregulate the granulomatous response in pulmonary sarcoidosis.

methodsRESOLVE-Lung was a double-blind, placebo-controlled trial in participants with chronic active pulmonary sarcoidosis on oral corticosteroids (OCS) and/or immunosuppressive therapies (IST). Participants were randomised (1:1) to receive 150 mg namilumab or placebo

resultsOf 209 participants screened, 107 were randomised to receive namilumab (n=53) or placebo (n=54). The proportion of participants with a rescue event was higher for the namilumab group (37.5%) compared with the placebo group (23.5%) (stratified difference 13.6 (90% CI -1.5-28.7) percentage points; p=0.12). The least squares (LS) mean change from baseline in forced vital capacity % predicted was -3.3 (90% CI -5.1- -1.5) percentage points for namilumab and -2.9 (90% CI -4.5- -1.3) percentage points for placebo (LS mean difference -0.4 (90% CI -2.7-2.0) percentage points). The proportion of participants successfully achieving OCS taper was 53.3% for namilumab and 76.9% for placebo (difference -19.4 (90% CI -47.5-8.7) percentage points). Treatment-emergent adverse events were reported in 94% in both groups, most being mild or moderate in severity.

conclusionIn participants with chronic active pulmonary sarcoidosis, namilumab did not provide clinical benefit.

Indexed as

Antibodies, Monoclonal, HumanizedSarcoidosis, PulmonaryAdrenal Cortex HormonesAdultAgedChronic DiseaseDouble-Blind MethodFemaleGranulocyte-Macrophage Colony-Stimulating FactorHumansImmunosuppressive AgentsMaleMiddle AgedTreatment OutcomeAdrenal Cortex HormonesAntibodies, Monoclonal, HumanizedGranulocyte-Macrophage Colony-Stimulating FactorImmunosuppressive Agents

Identifiers

PMID41819539
PMCPMC13347716

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.